Cargando…
Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma
OBJECTIVE: To investigate whether dose reductions in cisplatin due to renal dysfunction were associated with worse clinical outcomes in metastatic urothelial carcinoma (UC) patients. PATIENTS AND METHODS: One hundred and fifty one metastatic UC patients who received first‐line gemcitabine plus cispl...
Autores principales: | Murakami, Tetsushi, Kikuchi, Eiji, Ide, Hiroki, Umezawa, Yuta, Takahashi, Takayuki, Izawa, Mizuki, Hakozaki, Kyohei, Shigeta, Keisuke, Ogihara, Koichiro, Kobayashi, Hiroaki, Kanai, Kunimitsu, Maeda, Takahiro, Yoshimine, Shunsuke, Mizuno, Ryuichi, Nishimoto, Koshiro, Oya, Mototsugu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988766/ https://www.ncbi.nlm.nih.gov/pubmed/35474877 http://dx.doi.org/10.1002/bco2.81 |
Ejemplares similares
-
The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2021) -
Urinary pH is an independent predictor of upper tract recurrence in non-muscle-invasive bladder cancer patients with a smoking history
por: Ide, Hiroki, et al.
Publicado: (2021) -
Role of the MUC1‐C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2020) -
Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma
por: Shigeta, Keisuke, et al.
Publicado: (2022) -
IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer
por: Shigeta, Keisuke, et al.
Publicado: (2023)